ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 004

Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort

Jennifer Lee1, Simon Eng 2, Brian Feldman 3, Jaime Guzman 4, Kiem Oen 2 and Rae Yeung 3, 1University of Toronto, Toronto, Canada, 2Toronto, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4University of British Columbia and BC Children's Hospital, Vancouver, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: classification criteria, juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Plenary Abstracts Session 1

Session Type: Plenary Session I

Session Time: 2:30PM-3:30PM

Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain more homogeneous groups and improve alignment with adult criteria, when appropriate. We used data from the ReACCh-Out prospective inception cohort to assess 1) the degree of reclassification that would occur with the PRINTO system, and 2) whether reclassification would improve alignment with biologically defined subtypes and adult criteria for inflammatory arthritis.

Methods: JIA patients recruited from 16 Canadian centres between January 2005–December 2010 were considered. To facilitate fair comparisons, investigators were blinded to the original physician-assigned ILAR diagnoses and patients were computationally classified to PRINTO and ILAR systems with available data. In order to improve PRINTO classification, patients were considered ANA positive with ≥1 positive ANA reading. Patients were also evaluated under criteria for 4 adult arthritides (rheumatoid arthritis, psoriatic arthritis, adult-onset Still’s disease, and spondyloarthritis). Patients who provided biological samples were assigned to one of 4 biological subtypes as previously reported [1].

ILAR and PRINTO systems were compared to each other, and to biological and adult classification systems. Relationships were visualized with Circos plots and the degree of alignment was assessed with χ2 tests.

Results: 1,238 newly diagnosed (< 7 months) JIA patients with ≥1 follow-up visit were included. According to PRINTO criteria, most patients (783, 63%) were classified as other JIA, 244 (20%) had early-onset ANA-positive JIA, 159 (13%) had enthesitis/spondylitis-related JIA, 40 (3%) had systemic JIA, 12 (1%) had RF-positive JIA, and 0 had unclassified JIA. 1,111 patients (90%) had ANA information available.

We found significant associations between ILAR and PRINTO subtypes (χ2=2,503, p< 0.001). All patients with systemic or RF-positive polyarthritis (ILAR) were categorized as systemic or RF-positive JIA (PRINTO), respectively. 136 patients (62%) with enthesitis-related arthritis (ERA, ILAR) were categorized as enthesitis/spondylitis-related (PRINTO). Other JIA included ILAR-defined oligoarthritis (n=390, 50%), RF-negative polyarthritis (178, 23%), psoriatic arthritis (54, 6.9%), ERA (81, 10%), and undifferentiated arthritis (80, 10%).   In 132 patients (11%) with cytokine information, we identified associations between their biological subtypes and the ILAR system (χ2=46, p< 0.001) but not the PRINTO system (χ2=14, p=0.09) (Fig 1). Of 396 patients (32%) who satisfied adult criteria, fewer associations between the PRINTO system and adult arthritides were seen compared to the ILAR system (Fig 2, Table 1). No adult diagnosis was enriched for early-onset ANA-positive JIA.

Conclusion: Our findings suggest that adopting the preliminary PRINTO system would result in roughly two thirds of patients categorized as Other JIA and did not improve alignment with biologically defined groupings or adult classification criteria.

1. Eng SW et al. Arthritis Rheumatol. 2014; 66(12): 3463-75

Fig 1. Relationships between ILAR and PRINTO subtypes and biological subtypes.
Circos figures linking patient biological phenotypes (coloured wedges; middle) with ILAR (grey wedges; left) and PRINTO categories (grey wedges; right). Ribbon widths are proportional to the number of patients between pairs of biological subtypes and ILAR or PRINTO categories. Opaquer ribbons represent pairs that are significantly associated as determined by standardized residuals from χ2 tests.

Fig 2. Relationships between the ILAR categories, PRINTO categories, and adult classifications.
Circos figure linking computed ILAR categories (coloured wedges; left) with adult classifications (grey wedges; middle). Ribbons link patients shared between pairs of ILAR categories and adult classifications. Wider ribbons indicate more patients. Opaquer ribbons represent pairs that are significantly associated as given by standardized residuals from χ2 tests on the distributions of ILAR subtypes in each adult classification (Table 1). (B) Same as panel A, but for PRINTO categories (coloured wedges; right).

Table 1. Relationships between ILAR, PRINTO, and adult classifications.
p_values were Bonferroni_adjusted to account for multiple hypothesis testing.
—, adjusted p = 1.0.
AOSD: Adult_onset Still’s Disease, PsA: Psoriatic arthritis, RA: Rheumatoid arthritis, SpA: Spondyloarthritis


Disclosure: J. Lee, None; S. Eng, None; B. Feldman, OPTUM, Pfizer, AB2-Bio, 1; J. Guzman, None; K. Oen, None; R. Yeung, AbbVie, 1, 2, Novartis, 1, 2.

To cite this abstract in AMA style:

Lee J, Eng S, Feldman B, Guzman J, Oen K, Yeung R. Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/implications-of-adopting-the-newly-proposed-pediatric-rheumatology-international-trials-organization-printo-classification-criteria-for-juvenile-idiopathic-arthritis-jia-results-from-the-research/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implications-of-adopting-the-newly-proposed-pediatric-rheumatology-international-trials-organization-printo-classification-criteria-for-juvenile-idiopathic-arthritis-jia-results-from-the-research/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology